| Dr David Dorman Wright, MD | |
|
3960 W Royal Dr, Traverse City, MI 49684-9200 | |
| (231) 947-0404 | |
| (231) 947-2190 |
| Full Name | Dr David Dorman Wright |
|---|---|
| Gender | Male |
| Speciality | Obstetrics & Gynecology - Gynecology |
| Location | 3960 W Royal Dr, Traverse City, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538123500 | NPI | - | NPPES |
| 11292387 | Other | MI | CAQH |
| 2601322 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207VG0400X | Obstetrics & Gynecology - Gynecology | 4301047366 (Michigan) | Primary |
| Entity Name | Munson Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083761860 PECOS PAC ID: 3072426287 Enrollment ID: O20040108000904 |
News Archive
Algeta ASA has announced that with the results of the BC1-04 study reported today it has completed its comprehensive phase II clinical program evaluating Alpharadin (radium-223) as a new treatment for bone metastases in patients with hormone-refractory prostate cancer (HRPC).
"In October 1987, Roy Vagelos, then the chief executive of pharmaceutical company Merck, launched the largest pharmaco-philanthropic venture ever," William Foege, an epidemiologist and former director of the CDC, writes in a Washington Post opinion piece highlighting the company's efforts to combat onchocerciasis in the developing world through the free distribution of its drug Mectizan.
Siemens Financial Services, Inc., the U.S. unit of Siemens' Financial Services division, recently announced an expansion of its healthcare financing team and product capabilities. In addition to equipment financing, SFS Inc. now offers healthcare providers project, construction and permanent real estate financing, as well as asset-based and cash flow-based term loans.
Vertex Pharmaceuticals Incorporated today announced the U.S. Food and Drug Administration approved KALYDECO® (ivacaftor) to include use in children with cystic fibrosis ages 12 to <24 months who have at least one mutation in their cystic fibrosis transmembrane conductance regulator gene that is responsive to KALYDECO based on clinical and/or in vitro assay data.
If you feel that you are fated for cancer, your belief could turn into a self-fulfilling prophecy.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Dorman Wright, MD 3960 W Royal Dr, Traverse City, MI 49684-9200 Ph: (231) 947-0404 | Dr David Dorman Wright, MD 3960 W Royal Dr, Traverse City, MI 49684-9200 Ph: (231) 947-0404 |
News Archive
Algeta ASA has announced that with the results of the BC1-04 study reported today it has completed its comprehensive phase II clinical program evaluating Alpharadin (radium-223) as a new treatment for bone metastases in patients with hormone-refractory prostate cancer (HRPC).
"In October 1987, Roy Vagelos, then the chief executive of pharmaceutical company Merck, launched the largest pharmaco-philanthropic venture ever," William Foege, an epidemiologist and former director of the CDC, writes in a Washington Post opinion piece highlighting the company's efforts to combat onchocerciasis in the developing world through the free distribution of its drug Mectizan.
Siemens Financial Services, Inc., the U.S. unit of Siemens' Financial Services division, recently announced an expansion of its healthcare financing team and product capabilities. In addition to equipment financing, SFS Inc. now offers healthcare providers project, construction and permanent real estate financing, as well as asset-based and cash flow-based term loans.
Vertex Pharmaceuticals Incorporated today announced the U.S. Food and Drug Administration approved KALYDECO® (ivacaftor) to include use in children with cystic fibrosis ages 12 to <24 months who have at least one mutation in their cystic fibrosis transmembrane conductance regulator gene that is responsive to KALYDECO based on clinical and/or in vitro assay data.
If you feel that you are fated for cancer, your belief could turn into a self-fulfilling prophecy.
› Verified 2 days ago
Diana Lynn Novak, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3960 W Royal Dr, Traverse City, MI 49684 Phone: 231-947-0404 Fax: 231-947-2190 | |
Dr. Laura J Danz, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1200 6th St, Ste 400, Traverse City, MI 49684 Phone: 231-392-0650 Fax: 231-392-0665 | |
Dr. Jennie Rose, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 4400 Lands End, Traverse City, MI 49686 Phone: 231-944-4171 | |
Debra Joan Kurtz, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1200 Sixth St, Ste 400, Traverse City, MI 49684 Phone: 231-392-0655 Fax: 231-392-0665 | |
Dr. Don A Good, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1200 6th St, Ste 400, Traverse City, MI 49684 Phone: 231-392-0650 Fax: 231-392-0665 | |
Dr. Douglas L Mckay, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1200 6th St, Ste 400, Traverse City, MI 49684 Phone: 231-392-0650 Fax: 231-392-0665 | |
Dr. Marcy Verplanck-kanitz, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1200 6th St, Ste 400, Traverse City, MI 49684 Phone: 231-392-0650 Fax: 231-392-0665 |